To include your compound in the COVID-19 Resource Center, submit it here.

Spectrum’s value halved after poziotinib’s failure in NSCLC cohort

Eleven months after Spectrum divested its marketed products to sharpen its focus on a pair of clinical candidates, one of the two has failed in the first cohort of a Phase II trial, while the other is now under FDA review.

Shares of Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) sank $5.25 (60%) to $3.50

Read the full 516 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE